Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01834911 · ClinicalTrials.gov registry record · Phase 4
Effect of Tetrabenazine on Stroop Interference in HD
A Phase 4 study, sponsored by New York Medical College.
- Completed
- Registry status
- Phase 4
- Development phase
- 2
- Enrollment target
NCT01834911 is a Phase 4 study that has completed, run by New York Medical College. The registered enrollment target is 2 participants.
The verdict
NCT01834911, a Phase 4 study, has completed, sponsored by New York Medical College.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 2 participants
- Enrollment target
Study Summary
Tetrabenazine has been shown to improve gating of abnormal visual stimuli and improve postural stability in Huntington disease (HD) patients as measured by computerized dynamic posturography testing. This study aims to elucidate whether partial dopaminergic depletion via low dose tetrabenazine has a similar effect on masking out of abnormal visual stimuli on the Stroop interference test.
Interventions
- DRUG Tetrabenazine withdrawal
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2013-03 |
| Est. Completion | 2018-01-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01834911
The ClinicalTrials.gov registry entry for NCT01834911 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is New York Medical College, which has 47 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tetrabenazine withdrawal is the first listed.
NCT01834911 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01834911 about?
NCT01834911 is a clinical study titled "Effect of Tetrabenazine on Stroop Interference in HD". Tetrabenazine has been shown to improve gating of abnormal visual stimuli and improve postural stability in Huntington disease (HD) patients as measured by computerized dynamic posturography testing. This study aims to elucidate whether partial dopaminergic depletion via low dose tetrabenazine has a...
What is the current status of trial NCT01834911?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 2 participants. The study started on 2013-03. Estimated completion is 2018-01-01.
What interventions are being tested in trial NCT01834911?
The interventions under investigation include: Tetrabenazine withdrawal (DRUG).
Who is sponsoring clinical trial NCT01834911?
This trial is sponsored by New York Medical College, which has 47 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.